Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...

The Food and Drug Administration (FDA) accepted Pfizer’s application for an RSV vaccine for older adults, and is expected to make an approval decision by the spring. Pfizer in a statement on Wednesday ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer is rushing to get its respiratory syncytial virus (RSV) vaccine out the door and into arms. A priority review from the FDA will certainly help. The pharma giant announced Wednesday that U.S.

Thirteen essential drugs made at Pfizer’s Rocky Mount, N.C., facility — which was recently damaged by a tornado — have a vulnerability score higher than 90 percent, according to a July 26 report from ...

As Moderna’s COVID vaccine patent lawsuits wind their way through courts around the globe, Pfizer and BioNTech contend their rival is trying to monopolize the entire mRNA field. In the latest chapter ...

Pfizer (NYSE:PFE) announced Tuesday that the FDA accepted its Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate PF-06928316 for priority review targeting ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent ...

Pfizer has agreed to acquire weight-loss drugmaker Metsera in a transaction that could exceed $10 billion. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront, along with a ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus ...